Cargando…
A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation
Adaptive therapy is a dynamic cancer treatment protocol that updates (or ‘adapts’) treatment decisions in anticipation of evolving tumor dynamics. This broad term encompasses many possible dynamic treatment protocols of patient-specific dose modulation or dose timing. Adaptive therapy maintains high...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036119/ https://www.ncbi.nlm.nih.gov/pubmed/36952376 http://dx.doi.org/10.7554/eLife.84263 |
_version_ | 1784911574969876480 |
---|---|
author | West, Jeffrey Adler, Fred Gallaher, Jill Strobl, Maximilian Brady-Nicholls, Renee Brown, Joel Roberson-Tessi, Mark Kim, Eunjung Noble, Robert Viossat, Yannick Basanta, David Anderson, Alexander RA |
author_facet | West, Jeffrey Adler, Fred Gallaher, Jill Strobl, Maximilian Brady-Nicholls, Renee Brown, Joel Roberson-Tessi, Mark Kim, Eunjung Noble, Robert Viossat, Yannick Basanta, David Anderson, Alexander RA |
author_sort | West, Jeffrey |
collection | PubMed |
description | Adaptive therapy is a dynamic cancer treatment protocol that updates (or ‘adapts’) treatment decisions in anticipation of evolving tumor dynamics. This broad term encompasses many possible dynamic treatment protocols of patient-specific dose modulation or dose timing. Adaptive therapy maintains high levels of tumor burden to benefit from the competitive suppression of treatment-sensitive subpopulations on treatment-resistant subpopulations. This evolution-based approach to cancer treatment has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma. In the previous few decades, experimental and clinical investigation of adaptive therapy has progressed synergistically with mathematical and computational modeling. In this work, we discuss 11 open questions in cancer adaptive therapy mathematical modeling. The questions are split into three sections: (1) integrating the appropriate components into mathematical models (2) design and validation of dosing protocols, and (3) challenges and opportunities in clinical translation. |
format | Online Article Text |
id | pubmed-10036119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-100361192023-03-24 A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation West, Jeffrey Adler, Fred Gallaher, Jill Strobl, Maximilian Brady-Nicholls, Renee Brown, Joel Roberson-Tessi, Mark Kim, Eunjung Noble, Robert Viossat, Yannick Basanta, David Anderson, Alexander RA eLife Cancer Biology Adaptive therapy is a dynamic cancer treatment protocol that updates (or ‘adapts’) treatment decisions in anticipation of evolving tumor dynamics. This broad term encompasses many possible dynamic treatment protocols of patient-specific dose modulation or dose timing. Adaptive therapy maintains high levels of tumor burden to benefit from the competitive suppression of treatment-sensitive subpopulations on treatment-resistant subpopulations. This evolution-based approach to cancer treatment has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma. In the previous few decades, experimental and clinical investigation of adaptive therapy has progressed synergistically with mathematical and computational modeling. In this work, we discuss 11 open questions in cancer adaptive therapy mathematical modeling. The questions are split into three sections: (1) integrating the appropriate components into mathematical models (2) design and validation of dosing protocols, and (3) challenges and opportunities in clinical translation. eLife Sciences Publications, Ltd 2023-03-23 /pmc/articles/PMC10036119/ /pubmed/36952376 http://dx.doi.org/10.7554/eLife.84263 Text en © 2023, West et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cancer Biology West, Jeffrey Adler, Fred Gallaher, Jill Strobl, Maximilian Brady-Nicholls, Renee Brown, Joel Roberson-Tessi, Mark Kim, Eunjung Noble, Robert Viossat, Yannick Basanta, David Anderson, Alexander RA A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation |
title | A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation |
title_full | A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation |
title_fullStr | A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation |
title_full_unstemmed | A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation |
title_short | A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation |
title_sort | survey of open questions in adaptive therapy: bridging mathematics and clinical translation |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036119/ https://www.ncbi.nlm.nih.gov/pubmed/36952376 http://dx.doi.org/10.7554/eLife.84263 |
work_keys_str_mv | AT westjeffrey asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT adlerfred asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT gallaherjill asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT stroblmaximilian asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT bradynichollsrenee asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT brownjoel asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT robersontessimark asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT kimeunjung asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT noblerobert asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT viossatyannick asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT basantadavid asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT andersonalexanderra asurveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT westjeffrey surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT adlerfred surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT gallaherjill surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT stroblmaximilian surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT bradynichollsrenee surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT brownjoel surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT robersontessimark surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT kimeunjung surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT noblerobert surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT viossatyannick surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT basantadavid surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation AT andersonalexanderra surveyofopenquestionsinadaptivetherapybridgingmathematicsandclinicaltranslation |